Turing Pharmaceuticals CEO Martin Shkreli has not shied away from the public eye after being called out for raising the price of a critical drug by 5,000%.

Ahead of the Democratic presidential debate, where drug pricing is likely to be a key issue, we decided to catch up with Shkreli about his recent decision to hike the price of Daraprim, a drug used to treat parasitic infections in people with compromised immune systems, to $750 a pill from $13.50.

Here were our main takeaways:

He ?may be lowering the price, though it won't be immediately.

He's not getting off social media anytime soon.

He's not paying any attention to requests from government officials for more information about the drug price.